Ravi Salgia, MD

Ravi Salgia, MD, medical oncologist, professor, and chair, Department of Medical Oncology & Therapeutics Research, and Arthur & Rosalie Kaplan chair in Medical Oncology & Therapeutics Research at City of Hope Comprehensive Cancer Center, explains how treatment with a tyrosine kinase inhibitor (TKI) in patients with non–small cell lung cancer (NSCLC) can lead to disease transformation.

 mutations seen commonly in NSCLC require targeted therapy with an EGFR TKI. But, 5% to 7% of NSCLCs transform to small cell lung cancer (SCLC) following treatment with an EGFR TKI. Knowledge of the potential for transformation to SCLC lead Salgia et al to explore treatment with a novel PP2A inhibitor, 

LB-100 combined with chemotherapy or immunotherapy

Non–small cell lung cancer, as we know, can happen in many different types [of the disease]–and the type for adenocarcinoma especially– and a patient can have an 

 mutations, you get these targeted therapies, and they can potentially lead to small cell transformation. It's not very common, it happens in about 5% to 7% of the time in our clinical practice, after the patients receive a tyrosine kinase inhibitor.

Videos

Ravi Salgia, MD, explains how treatment with a tyrosine kinase inhibitor in patients with non–small cell lung cancer can lead to disease transformation.

EGFR Tyrosine Kinase Inhibitors and SCLC Transformation

Ravi Salgia, MD, professor and chair, Department of Medical Oncology & Therapeutics Research, associate director for clinical sciences, City of Hope, Durante, California, says there is a difference between precision medicine and personalized medicine.

Precision medicine and personalized medicine go hand-in-hand; however, personalizing care for patients with lung cancer requires oncologists to take a closer look at the patient&rsquo;s age, performance status, and other organ damage to decide whether or not the patient can tolerate a particular therapy. Once these details are considered, physicians can then practice precision medicine with the patients, says Salgia.

The ability to identify biomarkers, like an

mutation, is the key difference between precision medicine and personalized medicine. Knowing the patient&rsquo;s unique background and identifying these biomarkers helps physicians make the most educated decision regarding patients&rsquo; care.

Ravi Salgia, MD, professor and chair, Department of Medical Oncology &amp; Therapeutics Research, associate director for clinical sciences, City of Hope, Durante, California, says there is a difference between precision medicine and personalized medicine.

Ravi Salgia, MD | Authors

Articles

EGFR Tyrosine Kinase Inhibitors and SCLC Transformation

Understanding the Difference Between Precision Medicine and Personalized Care for Lung Cancer